Mechanism regulation of endoplasmic reticulum stress in multiple myeloma cells: modulation of the UPR, UPS, autophagy, HSPs, and potential therapeutic targets.
{"title":"Mechanism regulation of endoplasmic reticulum stress in multiple myeloma cells: modulation of the UPR, UPS, autophagy, HSPs, and potential therapeutic targets.","authors":"Ruth Angélica Lezama, Alexis Gudiño García, Karla López Ramírez, Jorge Vela Ojeda, Elba Reyes Maldonado, Zitlal-Lin Victoria-Avila","doi":"10.1080/17474086.2025.2574713","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Multiple myeloma (MM) progression results from complex interactions between tumor cells, cytokines, and the tumor microenvironment (TME). MM cells constantly produce paraprotein, causing endoplasmic reticulum stress (ERS). Cell survival relies on adaptive mechanisms such as the unfolded protein response (UPR), autophagy, and heat shock proteins (HSPs). This review emphasizes the role of ERS in MM cell survival and explores emerging therapeutic strategies targeting ERS-related pathways, including chemical agents, natural compounds, and inhibitors of autophagy, HSPs, or the proteasome.</p><p><strong>Areas covered: </strong>ERS in MM cells is a process that must be understood to provide a more complete understanding of this disease. This review analyzed review articles on ERS in normal cells, cancer, and MM, ERS proteins as drug targets in MM, and reports of scientific papers on ERS and MM. The articles were selected from PubMed from 1998 to 2025. and the Global Cancer Observatory website was also consulted.</p><p><strong>Expert opinion: </strong>The primary mechanisms regulating ERS are overexpressed in MM cells, and their inhibition can lead to apoptosis, making them potential therapeutic targets. ERS and autophagy are associated with changes in the immune cells of the TME, acting as an immune-evasive mechanism that promotes malignant progression.</p>","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2025-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17474086.2025.2574713","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Multiple myeloma (MM) progression results from complex interactions between tumor cells, cytokines, and the tumor microenvironment (TME). MM cells constantly produce paraprotein, causing endoplasmic reticulum stress (ERS). Cell survival relies on adaptive mechanisms such as the unfolded protein response (UPR), autophagy, and heat shock proteins (HSPs). This review emphasizes the role of ERS in MM cell survival and explores emerging therapeutic strategies targeting ERS-related pathways, including chemical agents, natural compounds, and inhibitors of autophagy, HSPs, or the proteasome.
Areas covered: ERS in MM cells is a process that must be understood to provide a more complete understanding of this disease. This review analyzed review articles on ERS in normal cells, cancer, and MM, ERS proteins as drug targets in MM, and reports of scientific papers on ERS and MM. The articles were selected from PubMed from 1998 to 2025. and the Global Cancer Observatory website was also consulted.
Expert opinion: The primary mechanisms regulating ERS are overexpressed in MM cells, and their inhibition can lead to apoptosis, making them potential therapeutic targets. ERS and autophagy are associated with changes in the immune cells of the TME, acting as an immune-evasive mechanism that promotes malignant progression.
期刊介绍:
Advanced molecular research techniques have transformed hematology in recent years. With improved understanding of hematologic diseases, we now have the opportunity to research and evaluate new biological therapies, new drugs and drug combinations, new treatment schedules and novel approaches including stem cell transplantation. We can also expect proteomics, molecular genetics and biomarker research to facilitate new diagnostic approaches and the identification of appropriate therapies. Further advances in our knowledge regarding the formation and function of blood cells and blood-forming tissues should ensue, and it will be a major challenge for hematologists to adopt these new paradigms and develop integrated strategies to define the best possible patient care. Expert Review of Hematology (1747-4086) puts these advances in context and explores how they will translate directly into clinical practice.